Last updated: 11/03/2018 17:16:51
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.

Trial of GSK1120212 and GSK1120212 in Combination with GEM in Japanese Subjects with Solid Tumors

GSK study ID
114784
See study documents
Clinicaltrials.gov ID
NCT01324258
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase I Trial of GSK1120212 and GSK1120212 in Combination with Gemcitabine in Japanese Subjects with Solid Tumors
Trial description: This is the first clinical experience in Japan with GSK1120212, a novel MEK inhibitor. This study is designed to identify recommended doses and regimens in Japanese subjects for the future development of GSK1120212.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:

Number of participants with adverse events as a measure of safety and tolerability

Timeframe: Until a subject has a Dose Limiting Toxicity, withdraws from the study or dies

Secondary outcomes:

To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax etc.) values for GSK1120212

Timeframe: Cycle0, Cycle1 Day1,8,15,22, Cycle2 Day1 in Part 1

To assess pharmacokinetics (PK) parameter (AUC, Cmax, tmax, etc.) values for GSK1120212 and Gemcitabine

Timeframe: Cycle1 Day15 in Part2

Number of participants with the indicated tumor response defined by RECIST v1.1

Timeframe: Every eight weeks during the study

Serum level of cyctokines

Timeframe: Cycle1 Day15 in Part1 and Part2

Tissue level of expression of the indicated protein including pERK and Ki67 if possible

Timeframe: Cycle1 Day15 in Part1 and Part2

Tissue level of gene mutation including BRAF and KRAS if possible

Timeframe: Cycle1 Day15 in Part1 and Part2

Interventions:
  • Drug: GSK1120212
  • Drug: Gemcitabine
    • Enrollment:
    19
    Primary completion date:
    Not applicable
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Solid Tumours
    Product
    trametinib
    Collaborators
    Not applicable
    Study date(s)
    January 2011 to July 2013
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    20+ years
    Accepts healthy volunteers
    No
    • Correspond Part 1 (Single agent) and Part 2 (Combination)
    • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
    • Correspond Part 1 (Single agent) and Part 2 (Combination)
    • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Correspond Part 1 (Single agent) and Part 2 (Combination)
    • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
    • Age 20 years old or older at consent given
    • Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
    • Negative for hepatitis B surface (HBs) antigen, hepatitis virus Bc (HBc) antibody, and HBs antibody. HBs antigen-negative subjects who test positive for both HBc antibody and HBs antibody or either of them may be eligible when their HBV DNA quantification result is negative
    • Negative HCV antibody test
    • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the time of the first dose of GSK1120212 until 16 weeks after the last dose of GSK1120212
    • A female subject is eligible to participate if she is of;Non-childbearing potential females or female subjects with child-bearing potential must agree to use contraception until four weeks after the last dose of GSK1120212 to sufficiently minimize the risk of pregnancy at that point Part 1 -Dose escalation single agent part
    • Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy. Subjects with primary brain tumor are excluded
    • Adequate organ system functions as defined below; Absolute neutrophil count≥1,200/uL Hemoglobin≥9g/dL Platelets≥75,000/uL PT/INR and APTT≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA Part 2 -Combination part
    • Tumor type criteria;Histologically or cytologically confirmed diagnosis of solid tumor malignancy. Eligible are the cancers for which gemcitabine has been approved in 4-week schedule;1,000mg/m2 weekly for 3weeks followed by 1 week rest at the 4th week, including non-small cell lung cancer, pancreatic cancer, biliary cancer, and urothelial cancer, to which gemcitabine monotherapy is considered to be appropriate
    • Adequate organ system functions as defined below; Absolute neutrophil count≥1,500/uL Hemoglobin≥9g/dL Platelets≥100,000/uL PT/INR and APTT1≤1.3xULN Albumin≥2.5g/dL Total bilirubin≤1.5xULN AST and ALT≤2.5xULN Creatinine≤ULN OR Calculated creatinine clearance≥50mL/min OR 24-hour urine creatinine clearance≥50mL/min Left ventricular Ejection fraction≥LLN by ECHO or MUGA
    Exclusion criteria:
    • Correspond Part 1 (Single agent) and Part 2 (Combination)
    • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures
    • Use of an investigational anti-cancer drug within 28 days or five half-lives, whichever is shorter preceding the first dose of GSK1120212. Or use of an other investigational drug within 28 days or five half-lives, whichever is longer preceding the first dose of GSK1120212
    • Previous treatment with a MEK inhibitor
    • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or subinvestigator, contraindicates their participation
    • History of interstitial lung disease or pneumonitis
    • Current use of a prohibited medication
    • Any major surgery, radiotherapy, or immunotherapy within 21 days before initiation of GSK1120212. Or chemotherapy regimens with delayed toxicity within 21 days before initiation of GSK1120212. Or chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the two weeks before initiation of GSK1120212
    • History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)
    • Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
    • QTc B≥480 msecs
    • History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks
    • History or evidence of current≥Class II congestive heart failure as defined by New York Heart Association
    • History or evidence of current clinically significant uncontrolled arrhythmias
    • History of HIV infection
    • Evidence of severe or uncontrolled systemic diseases
    • Unresolved toxicity greater than CTCAE (Version 3.0) Grade 1 from previous anti-cancer therapy except alopecia
    • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO)
    • Pregnant or lactating female
    • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
    • Concurrent condition that in the investigator’s opinion would jeopardize compliance with the protocol
    • Unwillingness or inability to follow the procedures outlined in the protocol Part 1 -Dose escalation single agent part
    • History of another malignancy
    • Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs Part 2 -Combination part
    • History of another malignancy

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Osaka, Japan, 589-8511
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Tokyo, Japan, 181-8611
    Status
    Study Complete
    Contact us

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    No longer a GSK study
    Actual primary completion date
    Not applicable
    Actual study completion date
    2013-08-07

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Results for study 114784 can be found on the GSK Clinical Study Register.
    Click here
    Access to clinical trial data by researchers
    Visit website